Clinical response to a single-dose methylphenidate challenge is indicative of treatment response at two months in adults with ADHD.

ABSTRACT: Stimulants such as methylphenidate (MPH) are the first-line pharmacological treatment for attention-deficit/hyperactivity disorder (ADHD). Although stimulants are effective at a group level, individual response varies, which advocates for tailored treatment approaches. Prior studies suggested that neurobiological measures following a single dose of stimulants are indicative of longer-term clinical response. To expand these findings, we tested whether an association between acute and longer-term treatment response can also be identified using measures commonly used in clinic. Sixty adults with ADHD completed clinico-neuropsychological measures, including the Barkley Adult ADHD Rating Scale-IV (BAARS-IV) and the Quantitative behavior (Qb) test, following a single dose of MPH (20 mg) and plac

SUBMITTER: Parlatini V 

PROVIDER: S-EPMC12501378 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature